Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.4.3.13 (
lysyl oxidase
)
1,248
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Acute lung injury (ALI) is accompanied by decreased lung compliance. However, a role of tissue mechanics in modulation of inflammation remains unclear. We hypothesized that bacterial lipopolysacharide (LPS) stimulates extracellular matrix (ECM) production and vascular stiffening leading to stiffness-dependent exacerbation of endothelial cell (EC) inflammatory activation and lung barrier dysfunction. Expression of
GEF-H1
, ICAM-1, VCAM-1, ECM proteins fibronectin and collagen,
lysyl oxidase
(
LOX
) activity, interleukin-8 and activation of Rho signaling were analyzed in lung samples and pulmonary EC grown on soft (1.5 or 2.8 kPa) and stiff (40 kPa) substrates. LPS induced EC inflammatory activation accompanied by expression of ECM proteins, increase in
LOX
activity, and activation of Rho signaling. These effects were augmented in EC grown on stiff substrate. Stiffness-dependent enhancement of inflammation was associated with increased expression of Rho activator,
GEF-H1
. Inhibition of ECM crosslinking and stiffening by
LOX
suppression reduced EC inflammatory activation and
GEF-H1
expression in response to LPS. In vivo,
LOX
inhibition attenuated LPS-induced expression of
GEF-H1
and lung dysfunction. These findings present a novel mechanism of stiffness-dependent exacerbation of vascular inflammation and escalation of ALI via stimulation of
GEF-H1
-Rho pathway. This pathway represents a fundamental mechanism of positive feedback regulation of inflammation.
...
PMID:Stiffness-activated GEF-H1 expression exacerbates LPS-induced lung inflammation. 2473 83